Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin

References

• Cox G, O'Byrne KJ. Matrix metalloproteinases and cancer. Anticancer Res 2001;21:4207–19
   PubMed Web of Science ®Google Scholar
• Murphy G, Cockett MI, Ward RV, et al. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95kDa and 72kDa gelatinases, stromelysins 1 and -2 and punctuated metallo-proteinase (PUMP). Biochem J 1991;277: 277–9
   Google Scholar
• Kahari VM, Saarialho-Kere U. Matrix metallo-proteinases in skin. Exp Dermatol 1997;6:199–213
   PubMed Web of Science ®Google Scholar
• Corcoran ML, Hewitt RE, Kleiner DE, et al. MMP-2: expression, activation and inhibition. Enzyme Protein 1996;49:7–19
   PubMedGoogle Scholar
• Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245–52
   PubMed Web of Science ®Google Scholar
• Bruner KL, Rodgers WH, Gold LI, et al. Transforming growth factor beta mediates the progesterone suppression of an epithelial metallo-proteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci USA 1995; 92:7362–6
   PubMed Web of Science ®Google Scholar
• Marbaix E, Donnez J, Courtoy PJ, et al. Progesterone regulates the activity of collagenase and related gelatinases A and B in human endometrial explants. Proc Natl Acad Sci USA 1992;89:11789–93
   PubMed Web of Science ®Google Scholar
• Hampton AL, Nie G, Salamonsen LA. Progesterone analogues similarly modulate endometrial matrix metalloproteinase-1 and matrix metalloproteinase-3 and their inhibitor in a model for long-term contra-ceptive effects. Mot Hum Reprod 1999;5: 365–71
   Google Scholar
• Rodgers WH, Matrisian LM, Giudice LC, et al. Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest 1994; 94:946–53
   PubMed Web of Science ®Google Scholar
• Salamonsen LA, Butt AR, Hammond FR, et al. Production of endometrial matrix metalloproteinases, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation. J Clin Endocrinol Metab 1997;82: 1409–15
   PubMed Web of Science ®Google Scholar
• Lockwood CJ, Papp C, Alvarez M, et al. Ovarian steroids regulate stromelysin-1 expression in human endometrial stromal cells. Society for Gynecologic Investigation, 41st Annual Meeting 1994, Abstract 0197
   Google Scholar
• Holinka CF. Aspects of hormone replacement therapy. Ann NY Acad Sci 1994;734:271–84
   PubMed Web of Science ®Google Scholar
• Mahavni V, Sood AK. Hormone replacement therapy and cancer risk. Cum Opin Oncol 2001;13:384–9
   PubMed Web of Science ®Google Scholar
• Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol 1993;83:931–5
   Google Scholar
• Katsuki Y, Shibutani Y, Aoki D, et al. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 1997;79:169–76
   PubMed Web of Science ®Google Scholar
• Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 1995;29: 736–42
   PubMed Web of Science ®Google Scholar
• Vincent AJ, Salamonsen LA. The role of matrix metalloproteinases and leucocytes in abnormal uterine bleeding associated with progestin-only contra-ceptives. Hum Reprod 2000;15:135–43
   PubMed Web of Science ®Google Scholar
• Marbaix E, Vekemans M, Galant C, et al. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users. Hum Reprod 2000; 15:120–34
   PubMed Web of Science ®Google Scholar
• Ishiwata I, Ishiwata C, Soma M, etal. Establishment of human endometrial adenocarcinoma cell line containing estradio1-17 beta and progesterone receptors. Gynecol Oncol 1984;17:281–90
   PubMed Web of Science ®Google Scholar
• Park DW, Ryu HS, Choi DS, et al. Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro. Gynecol Oncol 2001;82:442–9
   PubMed Web of Science ®Google Scholar
• Miyaki E, Yasumitsu H, Hirahara F, et al. Character-ization of matrix-degrading proteinases and their inhibitor secreted by human gynecological carcinoma cells. Jpn J Cancer Res 1995;86:568–76
   PubMedGoogle Scholar
• Ueda M, Fujii H, Yoshizawa K, et al. Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro. Jpn J Cancer Res 1996;87:524–33
   PubMedGoogle Scholar
• Soini Y, Alarakkola E, Autio-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in non-neoplastic and neoplastic endometrium. Hum Pathol 1997;28: 220–6
   Google Scholar
• Yabushita H, Narumiya H, Hiratake K, et al. The association of transforming growth factor-beta 1 with myometrial invasion of endometrial carcinomas through effects on matrix metalloproteinase. J Obstet Gynaecol Res 2000;26:163–70
   PubMedGoogle Scholar
• Iurlaro M, Loverro G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest 1999;29:793–801
   PubMed Web of Science ®Google Scholar
• Maatta M, Soini Y, Liakka A, et al. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neo-plastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation. Am J Clin Pathol 2000;114:402–11
   Google Scholar
• Van den Brule FA, Engel J, Stetler-Stevenson WG, et al. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast cancer cells. Int J Cancer 1992; 52:653–7
   PubMed Web of Science ®Google Scholar
• Zhang J, Hampton AL, Nie G, et al. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes coordinately expressed in human endometrium. Biol Reprod 2000;62:85–94
   PubMed Web of Science ®Google Scholar
• Irvin JC, Kirk D, Gwatkin RB, et al. Human endometrial matrix metalloproteinase-2, a putative menstruation proteinase. Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle. J Clin Invest 1996; 97:273–4
   Google Scholar
• Lockwood CJ, Krikun G, Hausknecht VA, et al. Matrix metalloproteinase and matrix metallo-proteinase inhibitor expression in endometrial stromal cells during progestin-initiated decidualization and menstruation-related progestin withdrawal. Endocrinology 1998;139:4607–13
   PubMed Web of Science ®Google Scholar
• Hickey M, Higham J, Sullivan M, et al. Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertil Steril 2001;75:288–96
   PubMed Web of Science ®Google Scholar